Michael Herold
Impact in
- Pathology and Forensic Medicine top 0.5%
- Lymphoma Diagnosis and Treatment
- Genetics top 1%
- Chronic Lymphocytic Leukemia Research
Papers in
-
- Lymphoma Diagnosis and Treatment 58
- Genetics 28
- Chronic Lymphocytic Leukemia Research 26
- Co-authors
- Wolfgang Hiddemann (31 shared papers)M. Schwoerer (9 shared papers)Robert Marcus (25 shared papers)John F. Seymour (9 shared papers)Tilmann Walk (20 shared papers)J. Gmeiner (6 shared papers)Hennicke Kamp (21 shared papers)W. Mellert (17 shared papers)
- Journals
- Blood (17 papers)Toxicology Letters (12 papers)Journal of Clinical Oncology (5 papers)Hematological Oncology (4 papers)Value in Health (3 papers)
- Partner nations
- GermanyUnited StatesSwitzerland
In The Last Decade
Michael Herold
132 papers receiving 3.4k citations
Michael Herold's Hit Papers
Peers
Comparison fields: 5 of 156
- Pathology and Forensic Medicine 1.7k
- Genetics 830
- Oncology 1.0k
- Reproductive Medicine 183
- Pharmacology 154
Countries citing papers authored by Michael Herold
This map shows the geographic impact of Michael Herold's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Herold with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Herold more than expected).
Fields of papers citing papers by Michael Herold
This network shows the impact of papers produced by Michael Herold. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Herold. The network helps show where Michael Herold may publish in the future.
Co-authors
The 25 scholars most cited alongside Michael Herold, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 138 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Obinutuzumab for the First-Line Treatment of Follicular Lymphoma Hit paper breakdown → | 2017 | 494 |
| 2 | 2007 | 391 | |
| 3 | 2018 | 152 | |
| 4 | 1999 | 133 | |
| 5 | 2017 | 129 | |
| 6 | Efficacy of bendamustine in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase I/II study of the German CLL Study Group. | 2005 | 106 |
| 7 | 2001 | 101 | |
| 8 | 2022 | 94 | |
| 9 | 2012 | 89 | |
| 10 | 2007 | 81 | |
| 11 | 1999 | 73 | |
| 12 | 2018 | 72 | |
| 13 | 1997 | 60 | |
| 14 | 2014 | 59 | |
| 15 | 1990 | 52 | |
| 16 | 2015 | 51 | |
| 17 | 1994 | 48 | |
| 18 | 1996 | 46 | |
| 19 | 2003 | 43 | |
| 20 | 2019 | 37 |
About Michael Herold
Michael Herold is a scholar working on Pathology and Forensic Medicine, Genetics, Molecular Biology, Oncology and Pulmonary and Respiratory Medicine, having authored 138 papers that have together received 3.6k indexed citations. Recurring topics across this work include Lymphoma Diagnosis and Treatment (58 papers), Chronic Lymphocytic Leukemia Research (26 papers), Metabolomics and Mass Spectrometry Studies (18 papers), Viral-associated cancers and disorders (15 papers), CNS Lymphoma Diagnosis and Treatment (8 papers), Organic Electronics and Photovoltaics (8 papers), Pharmacogenetics and Drug Metabolism (8 papers) and Monoclonal and Polyclonal Antibodies Research (7 papers). The work is most often cited by research in Pathology and Forensic Medicine (1.7k citations), Genetics (830 citations), Oncology (1.0k citations), Reproductive Medicine (183 citations) and Pharmacology (154 citations). Michael Herold has collaborated with scholars based in Germany, United States and Switzerland. Frequent co-authors include Wolfgang Hiddemann, M. Schwoerer, Robert Marcus, John F. Seymour, Tilmann Walk, J. Gmeiner, Hennicke Kamp, W. Mellert, Ingo Lenk and Christiane Gatz. Their work appears in journals such as Blood, Toxicology Letters, Journal of Clinical Oncology, Hematological Oncology and Value in Health.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.